The American Association of Clinical Endocrinologists (AACE) and the American College of Endocrinology (ACE) recently issued a joint position statement on the cardiovascular risks of testosterone therapy. In the statement, the two endocrinology groups questioned the FDA’s recommended method for determining whether a patient requires testosterone therapy and call for more research on the health risks posed by Low-T products.
The FDA has indicated that testosterone therapy is approved for use only in men with medically deficient testosterone, or hypogonadism. The agency has stressed that testosterone drugs like AndroGel and Testim should not be prescribed to men experiencing the natural effects of aging. Several recent studies have suggested a link between testosterone therapy and increased risk of stroke, heart attack, and death.
In light of this news, thousands of men have filed testosterone lawsuits, in which they allege companies such as AbbVie and Eli Lilly took advantage of consumers with deceptive advertising, and downplayed or concealed the health risks of their drugs. Roughly 2,500 of these testosterone lawsuits have been consolidated in an Illinois testosterone MDL.
The AACE and ACE take issue with how the FDA determines which patients should get testosterone prescriptions. The groups argue that this decision should be based not on the underlying cause of a patient’s low testosterone (hypogonadism), but on the signs and symptoms of the condition. The two organizations do, however, agree that testosterone therapy prescription should be accompanied by patient testing to ensure no one is exposed to undue risk, especially until cardiovascular risks of these drugs has been better quantified.
Did you or a loved one suffer a cardiovascular injury after receiving testosterone therapy? If so, you may be eligible to file your own testosterone replacement lawsuit and join the growing Illinois multidistrict litigation. Contact the testosterone lawyers at Lopez McHugh today to have an attorney review your case free of charge and confidentially.